Risankizumab clinical trials
Also written ABBV-066, SKYRIZI and BI 655066.
How each study uses risankizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the risankizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Apr 2019 · SKYRIZI · BLA 761105 (FDA, Drugs@FDA)
- European Union
- 26 Apr 2019 · Skyrizi · EMEA/H/C/004759 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2016 (8)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 7 |
| 2019 | 8 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 67 · Other 10
AbbVie (64) · Janssen Research & Development, LLC (2) · Jaehwan Kim (1) · Radboud University Medical Center (1) · Oregon Medical Research Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Boehringer Ingelheim (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Guselkumab (5) · Secukinumab (3) · Ixekizumab (3) · Bimekizumab (3) · Adalimumab (3) · Deucravacitinib (2) · Tildrakizumab (2) · Tacrolimus (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Risankizumab is the comparator. A study of two new drugs counts under both.
- 1Sonelokimab · MoonLake Immunotherapeutics AG · next primary completion Jan 2027
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test risankizumab, phase 3 first.
- Mar 2027A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.Phase 3 · AbbVie
- Aug 2027A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabPhase 3 · AbbVie
- Jan 2027A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsPhase 1 · AbbVie
Studies
Open first, then newest update. How each study uses risankizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 77
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisRecruitingPhase 2AbbVieNCT06865105Written as Risankizumab
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Janssen Research & Development, LLCNCT07499232Written as Risankizumab
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingPhase 2AbbVieNCT07697456Written as Risankizumab
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingPhase 3AbbVieNCT07071519Written as Risankizumab
- Risankizumab for Refractory Perianal Fistulizing Crohn's DiseaseRecruitingPhase 4Yuki HorioNCT07872449Written as Risankizumab
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3AbbVieNCT05995353Written as Risankizumab
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingPhase 2AbbVieNCT06548542Written as Risankizumab
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingPhase 3AbbVieNCT06100744Written as Risankizumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Risankizumab
- A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsRecruitingPhase 1AbbVieNCT07466550Written as Risankizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Risankizumab
- Risankizumab for Fibrostenotic Crohn's Disease TreatmentNot yet recruitingPhase 3First Affiliated Hospital of Wenzhou Medical UniversityNCT07177118Written as Risankizumab
- Risankizumab in Children With Crohn's Disease (RisaKids)RecruitingNot applicableShaare Zedek Medical CenterNCT06298188Written as Risankizumab
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)Active, not recruitingPhase 3AbbVieNCT03671148Written as Risankizumab
- A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseActive, not recruitingPhase 3AbbVieNCT03105102Written as Risankizumab IV
- A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingPhase 3AbbVieNCT06880744Written as Risankizumab
- Risankizumab Long-term Remission StudyCompletedPhase 4Jaehwan KimNCT04630652Written as Risankizumab-Rzaa
- A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseCompletedPhase 4AbbVieNCT06346288Written as Risankizumab
- A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedPhase 4AbbVieNCT06333860Written as Risankizumab
- Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)Active, not recruitingPhase 3AbbVieNCT04524611Written as Risankizumab
See all 77 studies that test risankizumab →
Given beside what is tested · 2 — risankizumab is usual care or a partner of the new treatment
- A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe PsoriasisNot yet recruitingPhase 2AbbVieNCT07933536Written as Risankizumab
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's DiseaseRecruitingPhase 3Weill Medical College of Cornell UniversityNCT06274554Written as IL-23 Therapy
As the comparator · 3 — what is tested is compared with risankizumab
- Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult ParticipantsRecruitingPhase 1Chong Kun Dang PharmaceuticalNCT07258745Written as SKYRIZI
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641089Written as Risankizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT06624228Written as Risankizumab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Risankizumab for Refractory Perianal Fistulizing Crohn's DiseaseOct 23, 2026NCT07872449
Codes
What other systems call risankizumab · ClinicalTrials.gg INT000320
- MeSH (NLM) C000601773risankizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 90ZX3Q3FR7RISANKIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2166040Confirmed FDA, Wikidata
- Wikidata Q25112466risankizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152227RisankizumabOne source FDA
- DrugBank DB14762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601773 | risankizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 90ZX3Q3FR7 | RISANKIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2166040 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25112466 | risankizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152227 | Risankizumab | One source FDA |
| DrugBank | DB14762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.